Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) shares were down 1.6% during trading on Wednesday . The stock traded as low as $89.08 and last traded at $90.26, with a volume of 890,869 shares traded. The stock had previously closed at $91.69.

Several research analysts recently commented on VRTX shares. Citigroup Inc. began coverage on shares of Vertex Pharmaceuticals in a research report on Tuesday, September 13th. They set a “market perform” rating on the stock. They noted that the move was a valuation call. Raymond James Financial Inc. began coverage on shares of Vertex Pharmaceuticals in a research report on Tuesday, September 13th. They set a “market perform” rating on the stock. Jefferies Group reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 31st. Credit Suisse Group AG reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, June 16th. Finally, Maxim Group reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, July 7th. Eleven research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. Vertex Pharmaceuticals has an average rating of “Buy” and a consensus price target of $118.45.

The stock’s market capitalization is $22.75 billion. The stock’s 50 day moving average price is $97.31 and its 200 day moving average price is $89.53.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/vertex-pharmaceuticals-inc-vrtx-trading-down-1-6.html

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Wednesday, July 27th. The pharmaceutical company reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.03. Vertex Pharmaceuticals had a negative net margin of 17.77% and a negative return on equity of 12.34%. The firm had revenue of $431.61 million for the quarter, compared to analyst estimates of $428.08 million. During the same period last year, the firm posted ($0.54) EPS. Vertex Pharmaceuticals’s quarterly revenue was up 159.9% on a year-over-year basis. On average, equities research analysts expect that Vertex Pharmaceuticals Inc. will post $1.00 EPS for the current fiscal year.

In other Vertex Pharmaceuticals news, Director Joshua S. Boger sold 5,140 shares of the business’s stock in a transaction on Wednesday, July 6th. The shares were sold at an average price of $88.99, for a total transaction of $457,408.60. Following the sale, the director now directly owns 273,365 shares in the company, valued at approximately $24,326,751.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Joshua S. Boger sold 6,500 shares of the business’s stock in a transaction on Wednesday, July 13th. The stock was sold at an average price of $88.81, for a total transaction of $577,265.00. Following the sale, the director now owns 274,725 shares in the company, valued at $24,398,327.25. The disclosure for this sale can be found here. 1.90% of the stock is currently owned by corporate insiders.

Several large investors have recently modified their holdings of VRTX. DnB Asset Management AS raised its stake in shares of Vertex Pharmaceuticals by 34.6% in the first quarter. DnB Asset Management AS now owns 18,280 shares of the pharmaceutical company’s stock valued at $1,453,000 after buying an additional 4,700 shares during the last quarter. Capstone Asset Management Co. raised its stake in shares of Vertex Pharmaceuticals by 4.2% in the first quarter. Capstone Asset Management Co. now owns 23,001 shares of the pharmaceutical company’s stock valued at $1,828,000 after buying an additional 930 shares during the last quarter. Factory Mutual Insurance Co. bought a new stake in shares of Vertex Pharmaceuticals during the first quarter valued at approximately $13,036,000. Commonwealth Equity Services Inc raised its stake in shares of Vertex Pharmaceuticals by 23.7% in the first quarter. Commonwealth Equity Services Inc now owns 6,999 shares of the pharmaceutical company’s stock valued at $556,000 after buying an additional 1,342 shares during the last quarter. Finally, Mn Services Vermogensbeheer B.V. bought a new stake in shares of Vertex Pharmaceuticals during the first quarter valued at approximately $428,000. Institutional investors own 96.19% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

5 Day Chart for NASDAQ:VRTX

Receive News & Ratings for Vertex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.